ArticlePersonalized medicine2009
Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses.
Article in Personalized medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Pooled it
- Do economic evaluations of targeted therapy provide support for decision makers?The American journal of managed care · 2011Pooled it
- Cost-effectiveness of precision medicine: a scoping review.International journal of public health · 2019Article
- Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Article
- Economic evaluations of personalized medicine: existing challenges and current developments.Pharmacogenomics and personalized medicine · 2015Review
- Genomic sequencing: assessing the health care system, policy, and big-data implications.Health affairs (Project Hope) · 2014Article
- Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.Current pharmacogenomics and personalized medicine · 2013Article
- A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.Breast cancer research : BCR · 2012Article
- Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.Medical care · 2011Article
- Do economic evaluations of targeted therapy provide support for decision makers?Journal of oncology practice · 2011Article
- Capacity building for assessing new technologies: approaches to examining personalized medicine in practice.Personalized medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Trastuzumab is a targeted therapy for human EGF receptor-2 (HER2)-positive breast cancer. The effectiveness and cost-effectiveness of trastuzumab hinges not only on its clinical efficacy in responding patients, but on the ability to accurately identify appropriate therapeutic candidates. We sought to systematically review the cost-effectiveness of trastuzumab with a focus on the impact of the test(s) used for HER2 diagnosis. Our review included 17 economic evaluations or health technology assessments of trastuzumab therapy or HER2 testing. Trastuzumab was considered cost-effective in all early-stage disease studies, while one author concluded that trastuzumab was not cost-effective for metastatic disease. Only two papers considered the joint effects of test accuracy and sequencing with trastuzumab therapy. These demonstrated that trastuzumab cost-effectiveness is sensitive to HER2-test properties.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.